Eli Lilly's oral GLP-1 candidate, Foundayo, is quietly building prescription momentum even after the company's second-quarter results fell short of Wall Street expectations. The latest data suggests that while financial headlines focused on the miss, the real story may be the drug's slow but steady uptake in a fiercely competitive metabolic market. Here's what the numbers reveal and why investors should keep an eye on this oral therapy.

The Q2 Disappointment and the Underlying Signal

Lilly's second-quarter earnings report, released earlier this month, painted a mixed picture. Revenue and earnings per share missed analyst consensus, triggering a sell-off in the stock. The miss was largely attributed to higher R&D spending and supply chain adjustments, but the company's pipeline narrative remained intact.

Yet, buried in the earnings call and subsequent prescription data was a notable trend: Foundayo, the company's oral GLP-1 receptor agonist, has been generating a growing number of new prescriptions week over week. While the absolute numbers are still modest compared to injectable blockbusters like Mounjaro, the trajectory is encouraging for a molecule that many had written off after early clinical setbacks.

Why Foundayo Matters in the Oral GLP-1 Race

The oral GLP-1 space is one of the most hotly contested in pharma, with rivals like Novo Nordisk's oral semaglutide already on the market. A convenient pill could capture patients who are averse to injections, expanding the overall addressable market. Foundayo's mechanism aims to deliver similar efficacy to injectables but with better tolerability and fewer gastrointestinal side effects, a key differentiator.

According to recent script tracking data, Foundayo's weekly new-to-brand prescriptions have climbed for five consecutive weeks, even as the company touted its long-term potential. This growth is happening without any major direct-to-consumer advertising push, suggesting organic interest from both physicians and patients.

Prescription Dynamics: What the Data Shows

A closer look at the prescription data reveals that Foundayo is not just converting patients from other GLP-1s but also attracting treatment-naive individuals. This is a positive sign for market expansion, as the biggest hurdle for oral GLP-1s has always been patient adherence and persistence.

  • New starts are up: Weekly new-to-brand prescriptions have increased by double digits month over month.
  • Physician adoption is broadening: More endocrinologists and primary care physicians are writing initial prescriptions.
  • Payer coverage is improving: Several major commercial insurers have recently added Foundayo to their formularies.

However, analysts caution that the absolute script counts are still a fraction of what Mounjaro or Ozempic achieve. The real test will come in the next few quarters, when Lilly scales up manufacturing and potentially launches a DTC campaign.

Comparing with Compe*****s

Novo Nordisk's Rybelsus (oral semaglutide) has been the standard for oral GLP-1 therapy, but its uptake has been limited by dosing complexities and moderate efficacy compared to injectables. Foundayo aims to improve on both fronts, with a once-daily formulation that requires no fasting restrictions—a major advantage over Rybelsus, which must be taken on an empty stomach.

Additionally, Lilly's strong presence in the obesity market through Zepbound (tirzepatide) could provide a cross-selling opportunity. Patients who start on an injectable may later switch to an oral maintenance dose, creating a long-term revenue stream.

Market Reaction and Future Outlook

Despite the Q2 miss, Lilly's stock has partially recovered as investors digest the Foundayo script data. The company reiterated its full-year guidance, which includes a gradual ramp-up for the oral drug. Management indicated that they expect Foundayo to become a significant growth driver by 2027, assuming regulatory approvals for additional indications.

Some analysts remain skeptical, pointing out that oral GLP-1s have historically underdelivered on commercial expectations. However, the current script trend, combined with Lilly's manufacturing scale and commercial muscle, makes Foundayo a wildcard that could surprise to the upside.

The oral GLP-1 tracker shows that while the headline numbers can disappoint, the underlying demand signals often tell a different story. Foundayo is building scripts, and that's a narrative worth following.

Key Takeaways

  • Resilience despite a miss: Lilly's Q2 disappointment doesn't negate the positive prescription trend for Foundayo.
  • Differentiation is key: The pill's easier dosing could be a game-changer in patient adherence.
  • Watch the next quarters: Sustained script growth will be the metric to monitor.
  • Competitive landscape: Foundayo is positioning itself as a serious challenger to oral semaglutide.

For now, the oral GLP-1 tracker is flashing green for Foundayo, and that's a signal no pharma watcher should ignore.